Mallinckrodt PLC has agreed to acquire Sucampo Pharmaceuticals Inc. for $1.2bn, including the assumption of the latter's debt. The deal most notably brings one significant marketed asset, and two late-stage candidates for rare diseases which are projected to generate up to $450m in peak sales between them, if approved.
Mallinckrodt Reduces Acthar Reliance With $1.2bn Sucampo Buy
Mallinckrodt is to acquire Sucampo Pharmaceuticals for about $1.2bn. The deal brings it a short-term sales boost from Amitiza, although the constipation treatment only has a few years left before generic competition hits. Longer-term hopes lie in two Phase III products for rare diseases.
